NCT06500494Active, not recruiting
To Describe How Well Vinorelbine Given Orally Works in Patients With a Breast Cancer After 2 Years of Treatment
Advanced Breast Cancer Patients Treated With Oral Vinorelbine: a Prospective and Retrospective, Observational Study - VINOREAL
Source: ClinicalTrials.gov · Last updated 2 Jul 2026
Brief summary (registry, in English)
This study looks at how well oral vinorelbine works in treating advanced breast cancer. It looks at women who have already had this treatment or are currently having it.
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 368 (estimated)
- First submitted
- 8 Jul 2024
- Start date
- 10 Sept 2024
- Primary completion date
- Sept 2028
- Lead sponsor
- Pierre Fabre Medicament
- Diseases
- Metastatic breast cancer
- NCT number
- NCT06500494
What you commit to
- Study type: Observational
- Planned participants: 368
- From 10 Sept 2024 to the primary completion date, Sept 2028
- 3 sites in 3 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- no exclusion criteria for patients in this study
Who the study is looking for
- Female aged ≥ 18 years (≥ 19 years for Algeria as per local regulation) at oral vinorelbine ( OV) -based treatment initiation
- Confirmed diagnosis of locally advanced or metastatic breast cancer eligible for chemotherapy
- Initiated OV-based treatment as per SmPC for advanced breast cancer between January 2011 and December 2020 for the retrospective cohort or, initiating oral vinorelbine treatment at enrollment for the prospective cohort
- Willing and able to complete the QoL questionnaire, PPQ and WPAI questionnaire for the prospective cohort
- Provision of informed consent or non-opposition to the patient (or next of kin/legal representative, if applicable) for the use of data, according to local regulations
Age in the registry: 18 years to - · Sex: Female · Does not accept healthy volunteers
Sites (3)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Tianjing Medical University Cancer Institute & Hospital Coordinator of this site? Confirm its status | Tianjin | China | Unknown status |
| Centre Hospitalo-Universitaire Mustapha, Hopital Mustapha, Place du 1er Mai 1945, Sidi M'Hamed Coordinator of this site? Confirm its status | Algiers | Algeria | Unknown status |
| Azienda Ospedaliera San Gerardo U.O. Oncologia Medica Coordinator of this site? Confirm its status | Monza | Italy | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.